REG - Cambridge Cognition - Cambridge Cognition secures Innovate UK grant

Cambridge Cognition HoldingsAnnouncement

11/07/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240711:nRSK9488Va&default-theme=true

RNS Number : 9488V  Cambridge Cognition Holdings PLC  11 July 2024

 

11 July 2024

 

Cambridge Cognition Holdings plc

(ÒCambridge CognitionÓ, the ÒCompanyÓ or the ÒGroupÓ)

 

Cambridge Cognition secures Innovate UK grant for Bio-Hermes 2 project

 

Cambridge Cognition Holdings plc (AIM: COG), which develops and markets
digital solutions to assess brain health, is pleased to have been selected to
provide voice and touchscreen cognitive assessments for the Global
AlzheimerÕs Platform FoundationÕs Bio-Hermes 2 project. Cambridge Cognition
is receiving grant funding from Innovate UK, the UKÕs innovation agency (as
included in the announcement dated 29 May 2024). Three of Cambridge
CognitionÕs CANTABª touchscreen cognitive tasks, measuring working memory,
episodic memory and processing speed, and a Winterlight speech and language
task will be used.

 

The Bio-Hermes 2 project aims to generate a world-leading dataset to improve
the understanding of how digital and blood-based biomarkers can be used to
predict the extent of AlzheimerÕs Disease pathology as detected by positron
emission tomography (PET) brain scans.  1,200 patients covering the clinical
spectrum of the disease, from normal ageing to mild cognitive impairment and
through to dementia, will be monitored for up to 24 months.

 

With such a sizeable sample of patients over a long period, the project will
generate a large dataset that will considerably add to the existing scientific
evidence for the CompanyÕs voice and touchscreen assessments. In particular,
it will be the first large dataset that the Company will have using both
CANTAB and Winterlight assessments, providing an opportunity to have combined
assessments for patients in the future to better address emerging needs in
AlzheimerÕs Disease drug development.

 

Matthew Stork, Chief Executive Officer of Cambridge Cognition, commented:

"We are delighted that our CANTAB and Winterlight solutions will be in the
Bio-Hermes 2 project and are grateful to Innovate UK for the funding. This
could be a groundbreaking study for Cambridge Cognition, and indeed for the
clinical field, as it could enable the company to be the first to provide a
combined all-in-one voice and touchscreen assessment for AlzheimerÕs disease
in the futureÕ.

 

 

Enquiries:

 

 Cambridge Cognition Holdings plc                     Tel: 012 2381 0700

 Matthew Stork, Chief Executive Officer

 Stephen Symonds, Chief Financial Officer

 Panmure Liberum Limited (NOMAD and Joint Broker)     Tel: 020 7886 2968

 Freddy Crossley / Emma Earl                          (Corporate Finance)

 Rupert Dearden                                       (Corporate Broking)

 Dowgate Capital Limited (Joint Broker)               Tel: 020 3903 7715

 David Poutney / James Serjeant

 Hudson Sandler (Financial PR and IR)                 Tel: 020 7796 4133

 Dan de Belder / Hattie Dreyfus                       cog@hudsonsandler.com (mailto:cog@hudsonsandler.com)

 

Notes to Editors

 

About Cambridge Cognition

 

Cambridge Cognition is a technology company developing digital health products
to better understand, detect and treat conditions affecting brain health. The
Company's software products assess cognitive health in patients worldwide to
improve clinical trial outcomes, identify and stratify patients early and
improve global efficiency in pharmaceutical and healthcare industries.

 

For further information visit: https://cambridgecognition.com/
(https://cambridgecognition.com/)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDKBLFFZDLEBBV